SOURCE: Callidus Software Inc.

Callidus Software Inc.

June 08, 2016 08:00 ET

Stemina Biomarker Discovery Selects CallidusCloud Marketing Automation

DUBLIN, CA--(Marketwired - Jun 8, 2016) - Callidus Software Inc. (NASDAQ: CALD), a global leader in cloud-based sales, marketing, learning and customer experience solutions, announced today that Stemina Biomarker Discovery, a biomarker discovery company focused on diagnosis and individualized treatment of neurological disorders, has selected CallidusCloud Marketing Automation.

Marketing Automation is delivered as part of CallidusCloud's Lead to Money suite, a SaaS suite designed to help businesses drive enterprise engagement, sales performance management and sales effectiveness throughout the sales cycle to close bigger deals, faster.

About CallidusCloud
Callidus Software Inc. (NASDAQ: CALD), doing business as CallidusCloud®, is the global leader in cloud-based sales, marketing, learning and customer experience solutions. CallidusCloud enables organizations to accelerate and maximize their lead to money process with a complete suite of solutions that identify the right leads, ensure proper territory and quota distribution, enable sales forces, automate configure price quote, and streamline sales compensation -- driving bigger deals, faster. Approximately 4,700 leading organizations, across all industries, rely on CallidusCloud to optimize the lead to money process to close more deals for more money in record time.

About Stemina Biomarker Discovery

Stemina Biomarker Discovery was founded in 2007 and is located in Madison, Wisconsin. Stemina is a biomarker discovery company focused on diagnosis and individualized treatment of neurological disorders including autism spectrum disorders. Stemina uses its proprietary metabolomics platform to identify changes in metabolism that can be biomarkers more effective diagnosis and treatment of autism and other neurological disorders. Stemina operates its business in two divisions: one focused on developing diagnostic tests for neurological disorders; and the other focused on screening chemicals and compounds for their potential to cause birth defects if a woman is exposed during pregnancy. Clients include pharmaceutical, chemical, cosmetics and consumer products companies, the U.S. Army and the Environmental Protection Agency.

©2016 Callidus Software Inc. All rights reserved. Callidus, Callidus Software, the Callidus Software logo, CallidusCloud, the CallidusCloud logo, Clicktools, SURVE, syncfrog, TrueComp Manager, ActekSoft, ACom3, iCentera, Webcom, Litmos, the Litmos logo, LeadFormix, Rapid Intake, 6FigureJobs, and LeadRocket are trademarks, service marks, or registered trademarks of Callidus Software Inc.

Contact Information